# Developmental perfluorooctane sulfonate (PFOS) exposure alters gene expression in nucleus accumbens and prefrontal cortex and impairs cognition in rats: A transcriptomic and mediation analysis

**Authors:** Shiwen Li, Hongxu Wang, Ana C. Maretti-Mira, Tomas K. D. Manea, Shaun Y. Kim, Lida Chatzi, Jesse A. Goodrich, Tanya L. Alderete, Nathan Young, Ruth I. Wood, Max T. Aung

PMC · DOI: 10.1016/j.ecoenv.2025.119648 · 2026-01-29

## TL;DR

Exposure to PFOS during development in rats alters gene activity in brain regions linked to decision-making and causes cognitive issues.

## Contribution

Identifies specific genes and pathways in the brain affected by PFOS exposure that mediate cognitive impairments.

## Key findings

- PFOS exposure altered gene expression in the nucleus accumbens, prefrontal cortex, and hippocampus.
- DEGs like NAT8F2 and ABCG3 were linked to impaired cognitive flexibility and impulsive decision-making.
- Pathways such as ECM-receptor interaction and glutathione metabolism were associated with PFOS effects.

## Abstract

Growing evidence suggests that developmental exposure to
perfluorooctanesulfonic acid (PFOS) is linked to neurobehavioral outcomes.
Pregnant female rats were exposed to PFOS (15 mg/L) or Tween vehicle through
drinking water until the offspring were weaned at three weeks of age. As adults,
cognitive flexibility and impulsive decision-making were assessed in 8
PFOS-exposed and 8 vehicle-exposed rats using extradimensional set-shifting and
delay discounting tasks, respectively. Cognitive flexibility was measured by the
number of trials required to reach the criterion, while impulsive
decision-making was quantified as the area under the curve (AUC) of the percent
preference for the large reward lever (% CHL), response omissions (% omit), and
response latency (in second) at delays of 0, 15, 30, and 45 s. Brain tissues
from the nucleus accumbens, prefrontal cortex, and hippocampus were extracted
for bulk RNA sequencing. Differential gene expression analysis and gene set
enrichment analysis were performed. Mediation analysis was performed to assess
the mediated effect of DEGs in the associations between PFOS and neurobehavioral
tests. We identified 62 differentially expressed genes (DEGs) in the nucleus
accumbens, 34 in the hippocampus, and 59 in prefrontal cortex tissues due to
PFOS exposure. We also found DEGs, including NAT8F2,
AC080157.1, ABCG3, and
ENSRNOG00000063145 mediated between PFOS and
neurobehavioral assessments. Pathways that were associated with both PFOS
exposure and neurobehavioral outcomes (% CHL and % omit) included extracellular
matrix-receptor interaction, focal adhesion, and glutathione metabolism in the
nucleus accumbens. Developmental PFOS exposure may alter gene expression in the
nucleus accumbens and prefrontal cortex and was associated with impaired
cognitive flexibility and impulsive decision-making. These exploratory findings
highlight potential pathways, including ECM-receptor interaction and glutathione
metabolism, that warrant further validation.

## Linked entities

- **Genes:** Nat8f2 (N-acetyltransferase 8 (GCN5-related) family member 2) [NCBI Gene 93673], Abcg3 (ATP binding cassette subfamily G member 3) [NCBI Gene 27405]
- **Chemicals:** perfluorooctanesulfonic acid (PubChem CID 74483), PFOS (PubChem CID 74483)
- **Species:** Rattus norvegicus (taxon 10116)

## Full-text entities

- **Genes:** COL6A3 (collagen type VI alpha 3 chain) [NCBI Gene 1293] {aka BTHLM1, BTHLM1C, DYT27, UCMD1, UCMD1C}, Akt1 (AKT serine/threonine kinase 1) [NCBI Gene 24185] {aka Akt}, ASPNAT (aspartate N-acetyltransferase) [NCBI Gene 339983] {aka CML3, NACED, NAT8-LIKE, NAT8L}, COL1A2 (collagen type I alpha 2 chain) [NCBI Gene 1278] {aka EDSARTH2, EDSCV, OI4}, NAT8 (N-acetyltransferase 8 (putative)) [NCBI Gene 9027] {aka ATase2, CCNAT, CML1, GLA, Hcml1, TSC501}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, GGT6 (gamma-glutamyltransferase 6) [NCBI Gene 124975], PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, MYC (MYC proto-oncogene, bHLH transcription factor) [NCBI Gene 4609] {aka MRTL, MYCC, bHLHe39, c-Myc}, AGER (advanced glycosylation end-product specific receptor) [NCBI Gene 177] {aka RAGE, SCARJ1, sRAGE}, IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, Txndc9 (thioredoxin domain containing 9) [NCBI Gene 280671], SLC9A3 (solute carrier family 9 member A3) [NCBI Gene 6550] {aka DIAR8, NHE-3, NHE3}, Pfas (phosphoribosylformylglycinamidine synthase) [NCBI Gene 287420], RENBP (renin binding protein) [NCBI Gene 5973] {aka RBP, RNBP}, PFAS (phosphoribosylformylglycinamidine synthase) [NCBI Gene 5198] {aka FGAMS, FGAR-AT, FGARAT, GATD8, PURL}, COL4A6 (collagen type IV alpha 6 chain) [NCBI Gene 1288] {aka CXDELq22.3, DELXq22.3, DFNX6}, COL4A5 (collagen type IV alpha 5 chain) [NCBI Gene 1287] {aka ASLN, ATS, ATS1, CA54}, COL1A1 (collagen type I alpha 1 chain) [NCBI Gene 1277] {aka CAFYD, EDSARTH1, EDSC, OI1, OI2, OI3}, GSTA1 (glutathione S-transferase alpha 1) [NCBI Gene 2938] {aka GST-epsilon, GST2, GSTA1-1, GTH1}, Abcg3 (ATP-binding cassette, subfamily G (WHITE), member 3) [NCBI Gene 498327] {aka RGD1565568}, ITGB4 (integrin subunit beta 4) [NCBI Gene 3691] {aka CD104, GP150, JEB5A, JEB5B}, Vom2r44 (vomeronasal 2 receptor 44) [NCBI Gene 266778] {aka Casrl1}, Pik3cb (phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit beta) [NCBI Gene 85243], PILRA (paired immunoglobin like type 2 receptor alpha) [NCBI Gene 29992] {aka FDF03}, GSTM4 (glutathione S-transferase mu 4) [NCBI Gene 2948] {aka GSTM4-4, GTM4}
- **Diseases:** hyperactivity (MESH:D006948), cytotoxicity (MESH:D064420), ASD (MESH:D000067877), ADHD (MESH:D001289), neurodevelopmental disorders (MESH:D002658), amoebiasis (MESH:D000562), neurotoxic (MESH:D020258), substance abuse disorders (MESH:D019966), cancers (MESH:D009369), neuronal death (MESH:D009410), major depression (MESH:D003865), liver dysfunction (MESH:D017093), neuroinflammation (MESH:D000090862), behavioral problems (MESH:D001523), neurodegeneration (MESH:D019636), alcohol use and abuse disorders (MESH:D000437), hepatic encephalopathy (MESH:D006501), glioma (MESH:D005910), mitochondrial dysfunction (MESH:D028361), neurobehavioral alterations (MESH:D019954), lung adenocarcinoma brain metastasis (MESH:D000077192), Parkinson's disease (MESH:D010300), anxiety (MESH:D001007), inflammatory (MESH:D007249), decision-making (MESH:D020195), colorectal cancer (MESH:D015179), cognitive deficits (MESH:D003072), diabetic complications (MESH:D048909), -related diseases (MESH:D000077733), neurodevelopmental diseases (MESH:D004194), impulsivity (MESH:D007174), psychosis (MESH:D011618), CHL (MESH:D006689), depression (MESH:D003866), Alzheimer's (MESH:D000544)
- **Chemicals:** methamphetamine (MESH:D008694), dopamine (MESH:D004298), BioRender (-), glutathione disulfide (MESH:D019803), glutamate (MESH:D018698), Glutathione (MESH:D005978), water (MESH:D014867), oil (MESH:D009821), Per- and polyfluoroalkyl substances (MESH:D005466), sucrose (MESH:D013395), ROS (MESH:D017382), PFOS (MESH:C076994), Tween (MESH:D011136), heroin (MESH:D003932)
- **Species:** Danio rerio (leopard danio, species) [taxon 7955], Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090], Rattus norvegicus (brown rat, species) [taxon 10116]
- **Mutations:** E326K, rs1859788, rs2405442
- **Cell lines:** HBMEC — Bos taurus (Bovine), Transformed cell line (CVCL_A1BE)

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12854093/full.md

---
Source: https://tomesphere.com/paper/PMC12854093